Previous Close | 156.00 |
Open | 156.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 155.00 - 160.00 |
52 Week Range | 152.00 - 329.00 |
Volume | |
Avg. Volume | 615,929 |
Market Cap | 13.186B |
Beta (5Y Monthly) | 0.36 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.57 |
Earnings Date | May 10, 2024 - May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for 4978.T
StemBioSys, Inc. (StemBioSys) announced today the launch of CELLvo™ Atrial Cardiomyocyte, a "chamber specific" human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CM) designed to function identically to human atrial cardiomyocytes. StemBioSys developed CELLvo™ Atrial Cardiomyocyte to empower pharmaceutical companies and academics with a more precise, efficient and cost-effective platform for screening new drug products in vitro for cardiotoxicity compared to animal models and other